Accost Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.14 M
- Company Age 26 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.38 M
About Accost Pharmaceuticals (India)
Accost Pharmaceuticals (India) Private Limited (APIPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 April 1998 and has a history of 26 years and nine months. Its registered office is in Rajendra Nagar,Patna., Bihar.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.14 M.
The company currently has active open charges totaling ₹0.38 M.
Krishna Jha, Amresh Prakash, Rakesh Kumar, and Four other members serve as directors at the Company.
Company Details
- Location Rajendra Nagar,Patna., Bihar
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U00304BR1998PTC008452
-
Company No.
008452
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Apr 1998
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Accost Pharmaceuticals (India)?
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishna Jha
|
Whole-Time Director | 28-Apr-1998 | Current |
|
Amresh Prakash
|
Whole-Time Director | 16-Jun-2000 | Current |
|
Rakesh Kumar
|
Whole-Time Director | 16-Jun-2000 | Current |
|
Gyanendra Dubey
|
Director | 14-Jun-2005 | Current |
|
Archana Prakash
|
Director | 16-Jun-2000 | Current |
|
Bharati Jha
|
Director | 28-Apr-1998 | Current |
Financial Performance of Accost Pharmaceuticals (India).
Accost Pharmaceuticals (India) Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Accost Pharmaceuticals (India)?
In 2017, Accost Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.38 M
₹0
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.04 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Dec 2005 | Syndicate Bank | ₹0.38 M | Open |
How Many Employees Work at Accost Pharmaceuticals (India)?
Unlock and access historical data on people associated with Accost Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Accost Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Accost Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.